, Volume 71, Issue 11–12, pp 1007–1014 | Cite as

Simultaneous Analysis of Zofenopril and Its Active Metabolite Zofenoprilat in Human Plasma by LC–ESI-MS Using Pre-Column Derivatization with p-Bromophenacyl Bromide



Zofenoprilat is an active metabolite of zofenopril, which is very unstable in plasma because of oxidative degradation of its thiol group. In this method, p-bromophenacyl bromide was used as derivatization reagent, immediately after plasma separation, to react with the free thiol group of zofenoprilat and form the derivative zofenoprilat-p-BPB. After acidification with 50% acetic acid, the derivatized plasma samples were extracted with methyl tert-butyl ether and separated on a C18 column with 40:60 (v/v) 10 mM ammonium acetate buffer solution containing 0.1% formic acid–acetonitrile as mobile phase. Calibration plots were linear over the concentration range 1–500 ng mL−1 for zofenopril and 2–1,800 ng mL−1 for zofenoprilat. The method was successfully used to study the bioavailability of zofenopril calcium capsules relative to that of zofenopril calcium tablets in healthy Chinese volunteers.


Column liquid chromatography Mass spectrometry Zofenopril Zofenoprilat p-Bromophenacyl bromide Derivatization Pharmacokinetics 


  1. 1.
    Ambrosioni E (2007) Am J Cardiovasc Drugs 7(1):17–24. doi: 10.2165/00129784-200707010-00002 CrossRefGoogle Scholar
  2. 2.
    Evangelista S, Manzini S (2005) J Int Med Res 33(1):42–54Google Scholar
  3. 3.
    Pasini AF, Garbin U, Nava MC, Stranieri C, Pellegrini M, Boccioletti V, Luchetta ML, Fabrizzi P, Lo Cascio V, Cominacini L (2007) Am J Hypertens 20(4):443–450. doi: 10.1016/j.amjhyper.2006.09.020 CrossRefGoogle Scholar
  4. 4.
    Buikema H, Monnink SH, Tio RA, Crijns HJ, de Zeeuw D, van Gilst WH (2000) Br J Pharmacol 130(8):1999–2007. doi: 10.1038/sj.bjp.0703498 CrossRefGoogle Scholar
  5. 5.
    Jemal M, Ivashkiv E, Teitz D, Cohen AI (1988) J Chromatogr B 428(1):81–92. doi: 10.1016/S0378-4347(00)83892-Xz Google Scholar
  6. 6.
    Dal Bo L, Mazzucchelli P, Marzo A (2000) J Chromatogr B 749(2):287–294. doi: 10.1016/S0378-4347(00)00419-9 CrossRefGoogle Scholar
  7. 7.
    Wu F, Gao F, Ding L, Mao X, Ma P (2009) J China Pharm Univ 40(4):353–358. doi: CNKI:SUN:ZGYD.0.2009-04-020 Google Scholar
  8. 8.
    Marzo A, Dal Bo L, Mazzucchelli P, Monti NC, Tettamanti RA, Crivelli F, Uhr MR, Ismaili S, Giusti A (1999) Arzneim-Forsch 49(12):992–996Google Scholar
  9. 9.
    Marzo A, Dal Bo L, Mazzucchelli P, Monti NC, Crivelli F, Ismaili S, Giusti A, Uhr MR (2002) Arzneim-Forsch 52(4):233–242Google Scholar

Copyright information

© Vieweg+Teubner Verlag | Springer Fachmedien Wiesbaden GmbH 2010

Authors and Affiliations

  1. 1.Department of Pharmaceutical AnalysisChina Pharmaceutical UniversityNanjingChina
  2. 2.Organization for State Drug Clinical TrialDermatology Hospital Affiliated to Chinese Academy of Medical SciencesNanjingChina

Personalised recommendations